Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors  by Oxford, J.S. et al.
REVIEW
Treatment of epidemic and pandemic influenza with neuraminidase and
M2 proton channel inhibitors
J. S. Oxford, S. Bossuyt, S. Balasingam, A. Mann, P. Novelli and R. Lambkin
Academic and Retroscreen Virology, Barts and the London, Queen Mary’s School of Medicine and
Dentistry, London, UK
A small armentarium of anti-influenza drugs now exists, and includes the M2 blockers
(amantadine and rimantadine) and the neuraminidase inhibitors (Relenza and Tamiflu).
The neuraminidase inhibitors have certain advantages, including a broader spectrum of
antiviral activity, including influenza A and B viruses. On the other hand, there is now
much clinical experience with the M2 blockers, and these drugs are inexpensive. It is clear
that influenza in different community groups needs to be managed in specific and
targeted ways. For example, in the over-65-years and at-risk groups, vaccination will
remain a mainstay of disease prevention. However, up to 40% of those in these groups
may fail to receive vaccine, and therefore the antivirals can be used therapeutically, or, in
defined circumstances, as prophylactics. At present, influenza is hardly managed in the
community. The infrequent global outbreaks, pandemics, present further problems. The
more extensive use of the two classes of antivirals, and also vaccines, in the important
interpandemic years will provide a very significant investment in health benefits in the
face of a new pandemic virus in an otherwise completely vulnerable population.
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Influenza is a difficult target for antiviral chemo-
therapists; it is a genetically mobile virus that has
two faces, the pandemic one and the epidemic one.
It is our contention in this review that most scien-
tific and clinical attention should be focused upon
the epidemic face of influenza and that new anti-
virals should be more aggressively used in the
years between pandemics. In the years that inter-
vene between pandemics (1919–56, 1958–67, 1969–
2001), the rates of hospitalization and premature
death are far in excess of those during the pan-
demic years. As a single example, UK at the time of
the millennium celebration witnessed nearly
20 000 deaths from influenza pneumonia and
bronchitis (Figure 1). In turn, such a focus on
the interpandemic period will lead to more ideas
about how drugs can be used against influenza
during a pandemic itself. In preparation for a
pandemic, many countries are now considering
the creation of stockpiles of the antiviral drugs
reviewed below.
It is quite clear that there are economic and
medical benefits in preventing hospitalization
caused by influenza in the interpandemic periods
[1]. Also, the number of productive days lost
because of influenza each year is very significant.
Therefore, it is not surprising, but also encoura-
ging, given the attitudes of the past, that new anti-
influenza drugs were developed towards the end
of the last century and more are in the pipeline as
we start a new millennium.
I N H I B I T O R S O F T H E V I R A L M 2
P R O T O N P U M P O F I N F L U E N Z A
A V I R U S
To combat influenza, a drug is needed that reaches
the respiratory tree and, particularly, the upper
regions of the nasal and throat mucosa and tra-
chea, where most infections are thought to begin
and thereafter focus [2]. More rarely, the virus
descends into the bronchi, bronchioles, and even
the alveoli, and destroys the cellular lining of the
lung. Thus, bronchopneumonia is the hallmark of
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a serious and life-threatening influenza virus
infection, rather than solid consolidation, which
more often follows superinfection of the lung with
Streptococcus pneumoniae [2–4]. The discovery of
amantadine (also called I-adamantanamine hydro-
chloride, Symmetrel or, more recently, Lysovir)
enabled us to break through these pharmacologic
barriers [5], allowing the molecule to be distribu-
ted preferentially in the airways. The drug has
significant antiviral effects against all influenza A
viruses in cell culture, including the most recent
H5 viruses, in animal model infections in mice,
and, most importantly, in humans. The method of
action has been well characterized as blocking of
the vital acidification function of the viral M2
channel [6]. Analysis of rare biopsy material estab-
lished that the drug was concentrated, to higher
levels than simple tissue distribution models pre-
dicted, in the upper respiratory tract [7]. However,
the most significant discovery was that amanta-
dine, and its molecular relative rimantadine, had
prophylactic and therapeutic activity in human
infection with influenza A H1N1, H2N2 and
H3N2 viruses. At the start of this work nearly
40 years ago, amantadine was most studied in the
UK, Europe and Japan, while rimantadine was
investigated in very large trials in Russia, the
USA and, to a lesser extent, eastern Europe. These
extensive studies will be summarized briefly below
and can be easily consulted [8]. The prophylactic
activity, around 80–90%, is similar to that of the
recent neuraminidase (NA) inhibitors [9,10], as is
thetherapeuticactivity,reducingillnessbyapproxi-
mately 1.5 days if the drug is used within 36–48 h
of symptoms appearing. In fact, the scientific com-
munity did not accept that an anti-influenza drug
could have any therapeutic activity until the first
studies with amantadine proved otherwise.
In commercial terms, and in view of the invest-
ment of some £300 million needed to develop any
new drug, pharmaceutical companies need to be
assured of a market. However, examination of the
history of the underuse of amantadine and riman-
tadine illustrates the difficulty of introducing anti-
virals into the management of influenza in the
community. Amantadine and rimantadine have
been licensed as anti-influenza A drugs for four
decades, but their application in the community
has been bedevilled by two worries: emergence of
drug resistance, and fear of toxicity. As regards
toxicity, most earlier clinical studies employed a
dosage of 200 mg/day of amantadine. Some ‘jit-
teriness’ was noted in about 10% of patients, par-
ticularly the elderly. Significantly, some studies
[11] indicated that the dose could be halved to
100 mg daily, with continued anti-influenza A
activity. At this drug level, toxicologic problems
would not be expected, but the dosage can still be
adjusted downwards for the frail elderly, who
could be very underweight. We will return to this
important low-dose study below.
The problem of drug resistance is more difficult
to resolve, but is not unique to amantadine. Aman-
tadine-resistant mutants can be generated among
experimentally infected mice, but only after the
use of very high concentrations of drug [12]. It is
not known whether these viruses are less patho-
genic or virulent than the wild-type virus, but the
Figure 1 Mortality from influenza,
pneumonia and bronchitis in the UK
at the millennium 1999–2000.
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low frequency of detection in the field does sug-
gest this. Mutations which confer resistance to
amantadine can be clearly identified in the viral
M2 gene, and such viruses are cross-resistant to
other M2 proton channel inhibitors.
C L I N I C A L T H E R A P E U T I C E F F E C T S
O F A M A N T A D I N E
Clinical trials with amantadine or rimantadine
have been carried out over four decades in at least
eight countries, involving over 30 000 volunteers
or patients, with over 14 500 receiving amantadine.
The overall protection rate in prophylactic trials
against illness caused by influenza A H2N2, H3N3
or H1N1 viruses has varied between 50% and 100%.
In the majority of controlled therapeutic studies
with amantadine or rimantadine, a reduction in
the severity and duration of influenza-caused fever
was reported in those groups receiving the drug,
compared to the control groups, provided that
treatment was begun within 2 days of the onset of
the clinical symptoms.
Arguably, the most significant discovery for the
future development of antivirals against respira-
tory viruses was that of the therapeutic effect of
amantadine. In the initial studies, volunteers were
artificially infected with influenza virus and then
given amantadine or placebo. Symptoms, including
objective parameters such as temperature, sub-
sided more rapidly when amantadine was admi-
nistered [8].
Perhaps not surprisingly, the use of the antiviral
much later than 48 h after the diagnosis of clinical
disease failed to abrogate symptoms of the disease.
A similar situation has been documented with the
new anti-NA drugs. It should be noted that, prior
to these trials with amantadine, most virologists
considered that, concomitant with respiratory
symptomatology, virus replication would reach
a peak and the therapeutic use of an inhibitor
at this stage of the disease would be fruitless.
Surprisingly, few studies have actually been per-
formed on the quantity of influenza virus excreted
in the lower respiratory tract of infected humans.
Post-mortem examination of trachea specimens by
immunofluorescence and cytology during the
influenza A H2N2 pandemic did show that virus
replication was patchy and that many cells remain-
ed uninfected [2,4]. This observation would give
credence to the concept that therapeutic interven-
tion with antiviral drugs would prevent the spread
of virus further down the respiratory tract. En-
couragingly, pharmacologic experiments, in both
animals and humans, have shown a preferential
accumulation of amantadine in respiratory tissue,
including the lung [8]. Therefore, the scientific
basis for therapy with M2 blockers appears firm.
In a typical example of clinical investigations at
the time, two therapeutic studies were carried out
in the winters of 1972–73 and 1973–74 in general
practice in the UK. Both influenza A and influenza
B were circulating. As the influenza A viruses
during both winters had essentially the same sen-
sitivity in vitro to amantadine, the authors con-
sidered it appropriate to combine the results from
the two winters. The mean duration of fever in the
drug-treated group was 51.4 h, and that in the
controls was 73.4 h (P< 0.05). Symptoms cleared
completely within 4 days in 53% of patients receiv-
ing amantadine, compared with only 23% of
controls. Mean days in bed were 2.58 for the
amantadine group and 3.44 for the placebo group
(P< 0.01). In those patients with influenza B, there
were no significant differences between active
drug and placebo. The appearance of influenza B
infection,confirmedonlyafter theclinical recording
was completed, illustrated the sensitivity of the
trial design, for it had been demonstrated pre-
viously [5] that this virus was insensitive to aman-
tadine. No adverse effects were noted in this trial,
which employed 200 mg of amantadine each day.
C L I N I C A L S T U D I E S W I T H
L O W - D O S E ( 1 0 0 m g ) A M A N T A D I N E
Because of concern about the mild toxic effects of
200 mg amantadine per day, it is relevant to briefly
review clinical trials where lower doses were used,
and which showed that most adverse effects could
be avoided while antiviral activity was retained.
In the late 1960s [13], Smorodintsev et al. per-
formed two trials, the first with 100 mg (38 cases)
or 200 mg of amantadine as a single or divided
dose (168 cases) or placebo (198 cases) daily for
11 days in healthy volunteers who were chal-
lenged with virus 24 h after starting treatment.
One hundred and thirty-two of 146 (90.4%) of
placebo subjects developed influenza. In three
groups receiving amantadine (different strains of
influenza A), the rates were 49%, 33%, and 35%
(P 0.01). Fever was reduced from 64% in volun-
teers receiving placebo to 25% in volunteers rec-
eiving amantadine (P< 0.01). In those subjects
 2003 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 9, 1–14
Oxford et al Treatment of epidemic and pandemic influenza 3
developing influenza, dosing with amantadine
resulted in milder symptoms and a shorter dura-
tion of illness (8.2% longer than 7 days versus 49%
longer than 7 days on placebo). In this study, there
were no significant antiviral differences between
low-dose 100 mg and 200 mg amantadine daily.
Younkin et al. [14] treated influenza patients for
5 days with amantadine 100 mg (16 cases) or
200 mg (14 cases), or 3.25 g of aspirin (17 cases),
daily. Although the aspirin treatment group
defervesced more rapidly, by the second day the
amantadine-100 mg recipients showed greater
symptomatic improvements (P< 0.01). The 200-
mg dose did not show such significance. Bother-
some side effects resulted in discontinuation of
therapy by 35% of patients on aspirin but only 3%
of patients on amantadine. At 100 mg, the side
effects reported were considered to be minimal,
and consisted of dizziness, loss of concentration, or
insomnia. The study also demonstrated that
100 mg/day amantadine had therapeutic efficacy
equal to 200 mg/day.
Sears and Clements [15] induced influenza in 44
healthy volunteers; 22 received 100 mg of amanta-
dine, and 22 placebo, once daily for 8 days, with
intranasal viral challenge on day 4. Influenza ill-
ness was seen in two of 22 volunteers (9%) on
amantadine versus nine of 22 (41%) on placebo
(P< 0.04). With amantadine, the illness was mild
and tended to consist only of mild transient rhi-
nitis. Infection was seen in 77% of volunteers on
amantadine versus 91% of volunteers on placebo.
Virus shedding was reduced significantly by
amantadine during (P< 0.003) and after (P< 0.03)
treatment, with total days of virus isolation during
treatment being 1.2 on amantadine and 3.5 on
placebo. The amount of virus shed was halved by
low-dose amantadine treatment.
Reuman et al. [11] carefully investigated the
antiviral effects and also toxicity of low-dose
(100 mg) amantadine, and compared the results
with those of a group given 200 mg of the drug. In
this direct virus challenge experiment, 100 mg of
amantadine reduced the rate of illness from 58% to
15%, and the number of volunteers infected from
95% to 60% (Table 1).
Analysis of the three groups for central nervous
system and gastroenteritis effects showed no
increase in the low-dose (100 mg) drug group
compared to the placebo group (Table 2).
Treatment
group
Number of
subjects
Number
infected P-value
Number
ill P-value
Placebo 19 18 (95%) 11 (58%)
50 mg/day
amantadine 20 16 (80%) 0.187 4 (20%) 0.017
100 mg/day
amantadine 20 12 (60%) 0.012 3 (15%) 0.005
200 mg/day
amantadine 19 13 (68%) 0.045 2 (11%) 0.003
Influenza infection is defined as virus isolation, antibody response, or both.
Influenza illness is defined as fever >37.8 8C and two influenza symptoms [11].
Table 1 Protective effect of low-
dose amantadine in 78 subjects
challenged with influenza A virus
Placebo
Amantadine
100 mg (low dose)
Amantadine
200 mg
Total no. of subjects at risk 159 159 158
Total no. of subjects
with adverse experiences
49 (31%) 47 (30%) 71 (45%)a
Central nervous
system
25 (15%) 23 (14%) 47 (30%)
Gastrointestinal 12 (8%) 12 (8%) 17 (11%)
Cardiovascular 1 (0.6%) 1 (0.6%) 1 (0.6%)
Whole body 24 (15%) 16 (10%) 21 13%)
aSignificantly different compared to placebo (P¼ 0.009) and the 100-mg group
(P¼ 0.005).
Table 2 Absence of toxicity of low-
dose amantadine in community
studies [11]
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In conclusion, it would appear that amantadine
or rimantadine should be considered very serious-
ly in any modern clinical management strategy
for influenza. They are not effective against influ-
enza B, but are well tested antivirals that are
relatively safe and very cheap.
T H E N E U R A M I N I D A S E I N H I B I T O R S :
A M O D E R N D E V E L O P M E N T O F
A N A N T I V I R A L D R U G
Not until the early 1970s was the existence of a
physically separate NA enzyme spike established
[4]. The virus was known from earlier and classic
studies to possess NA activity per se, but physical
separation techniques, electron microscopy, reas-
sortment genetics and serology by immunodouble
diffusion established NA as a distinct mushroom-
shaped protein. The molecule was crystallized by a
scientist who, rather uniquely, had developed the
techniques of scale-up protein chemistry in an
academic laboratory [16]. Using cellulose acetate
strips, he was able to separate NA and haemag-
glutinin (HA), and, indeed, performed peptide
mapping on a viral protein for the first time.
The NA crystals themselves were not easy to
obtain in a high-quality form, but it was possible
to perform X-ray crystallography from such crys-
tals and to establish the position of antigenic epi-
topes and, importantly, the enzyme active site [17].
Much earlier, two chemists in Vienna [18] had
synthesized inhibitors of influenza NA, but the
molecules had failed to show any in vivo activity.
However, with new knowledge of NA crystal
structure and the precise localization of the normal
sialic acid substrate in the active site [19], it was
possible to design a sialic acid look-alike molecule
that would fit even more tightly in the active site of
the NA. This molecule, now known as zanamivir
or Relenza, was a very active inhibitor of a range of
influenza A and B viruses of all subtypes, includ-
ing those of birds, animals and humans. More
interestingly, given by aerosol or spray, the com-
pound inhibited virus replication in influenza-
infected mice, ferrets, and human volunteers.
The activity of the NA enzyme is essential for
the replication of influenza A and B viruses,
enabling the virus to negotiate nasal fluid packed
with sialic acid proteins when it enters the body,
and at the time of virus release from the infected
cell. Although most of the NA protein varies
between influenza strains, X-ray crystallography
and site-directed mutagenesis show that the amino
acid sequence and three-dimensional structure of
the enzyme’s active site are conserved [20]. In
particular, the 11 key amino acid residues that line
the shallow pocket of the enzyme active site and
interact directly with the substrate (sialic acid) are
highly conserved in all strains of influenza A and B
investigated, even the 1918 influenza virus. This
finding is important for two reasons. First, drugs
that mimic the natural substrate sialic acid and act
as competitive inhibitors should have broad inhi-
bitor activity. Second, the uniformity of the influ-
enza NA active site underlines the importance of
its three-dimensional structure for enzymatic
function, and suggests that development of resis-
tant strains could be hindered, as any change in
this vital structure might reduce the viability of the
virus [21]. Once this important discovery had been
made, NA inhibition became an attractive concept
for antiviral intervention.
Other innovative compounds that incorporate a
carbocyclic structure into the molecule have also
been developed; this arrangement offers greater
stability than that of earlier compounds, and facil-
itates modification of the molecule to optimize its
properties. One carbocyclic compound is (3R,4R,
5S)-4-acetamido-5-amino-3-(1-ethylopropoxy)-
1-cyclohexane-1-carboxylic acid, also known as
oseltamivir or Tamiflu [22,23]. This compound fits
precisely into the three-dimensional structure of
the NA active site to interact with conserved resi-
dues and competitively inhibit the enzyme. The
incorporation of a lipophilic side-chain into this
molecule exploits X-ray crystallographic evidence
of a hydrophobic pocket in the NA active site,
enhancing the affinity for the target. More recently,
a third and fourth inhibitor have been synthesized
[24–26].
R E P R E S E N T A T I V E C L I N I C A L
T R I A L S W I T H T H E
N E U R A M I N I D A S E I N H I B I T O R S
The efficacies of zanamivir and oseltamivir have
been demonstrated in the prevention (prophylaxis)
and in the treatment of experimental influenza
infection [27]. Hayden et al. reported the results
of four randomized, double-blind, placebo-con-
trolled trials that evaluated intranasal zanamivir
(two to six times daily) in the prevention and
treatment of experimental influenza A (H1N1) in
artificially infected volunteers. Overall, the drug
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prevented laboratory-proven infection and febrile
illness in 82% and 95% of subjects, respectively
(both P< 0.001 versus placebo). Early treatment of
experimental infection with zanamivir in these
studies reduced peak viral titers, the duration of
viral shedding, the frequency of illness and other
measures of illness compared with placebo.
Subsequent clinical studies in the community
showed that administration of inhaled drug within
48 h of natural influenza A or B infection signifi-
cantly reduced the duration of symptomatic illness
by 1 day (4 days versus 5 days) compared with
placebo. Importantly, data also indicated that
zanamivir treatment reduces the impact of influ-
enza virus infection on patients’ productivity and
health status and the number of contacts made
with healthcare professionals [28–30].
To study the therapeutic effect of zanamivir,
Monto et al. [30] analyzed the overall intent-to-
treat (ITT) population, and showed that the drug
reduced the median number of days to alleviation
of clinically significant symptoms by 1 day com-
pared with placebo (6 versus 7 days; Table 3).
This difference was statistically significant for
both zanamivir treatments (P¼ 0.012 twice daily
versus placebo, P¼ 0.014 four times daily versus
placebo). The difference between the zanamivir
and placebo groups was evident by inspection
by day 2, and was maintained until the end of
treatment. For patients who began treatment>30 h
after onset of symptoms, the difference between
the zanamivir and placebo groups, although
still present, was reduced to 0.5–1 day; this dif-
ference was not statistically significant. Zanamivir
reduced the time to symptom alleviation in both
febrile and non-febrile patients, but had a
greater effect on febrile patients. Zanamivir given
twice daily reduced the median time to alleviat-
ion of symptoms by 0.75 days in the non-febrile
group (P¼ 0.049) and by 1.5 days in the febrile
group (P¼ 0.049). Similar differences were seen
for zanamivir four times daily, compared with
placebo.
Of the persons who were febrile on study entry,
348 (74%) were influenza positive by isolation and
serology; only 57% of the total ITT population was
influenza positive. This suggests that a febrile state
early in the course of infection may be a good
marker for distinguishing between influenza-like
illnesses in the adult population. Similar benefits
(not shown) regarding symptom alleviation were
seen in the corresponding analyses for the influ-
enza-positive population. A reduction of 1.5 days
in the time to symptom alleviation was seen in
both zanamivir groups for the total influenza-
positive population, although the differences were
not statistically significant.
In rather similar treatment studies, the oral drug
oseltamivir (20, 100 or 200 mg twice daily or 200
mg once daily) was initiated 28 h after inoculation
with influenza virus. In patients with proven infec-
tion, the drug reduced the median area under the
curve (AUC) of viral titer in nasal washes for all
treatment groups, compared with placebo, produ-
cing a 100-fold reduction in viral load by 24 h and a
100-fold reduction by 36 h after treatment. The
median duration of influenza virus shedding
was reduced from 107 h in the placebo group to
58 h in the oral drug treatment group. There were
significantly ameliorated clinical symptoms, with
more rapid cessation of symptoms in the active
drug treatment groups, the duration of symptoms
Table 3 Median number of days to alleviation of major symptoms in influenza-diagnosed patients given zanamivir
Placebo Zanamivir 2/day Zanamivir 4/day
Population group No. Days No. Days P Differencea No. Days P Differencea
All patients
symptom durationb
422 7.0 419 6.0 0.012 1.0 415 6.0 0.014 1.0
30 h 249 6.5 242 5.5 0.015 1.0 240 5.0 0.001 1.5
>30 h 173 7.0 177 6.0 0.422 1.0 175 6.5 0.837 0.5
Feverb <37.8 8C 246 6.5 254 5.75 0.049 0.75 259 6.0 0.274 0.5
Feverb >37.8 8C 170 7.0 155 5.5 0.049 1.5 148 5.0 0.032 2.0
High-risk patients 68 7.8 48 6.3 0.137 1.5 42 5.0 0.042 2.75
aDifference from placebo (95% confidence interval).
bAt study entry.
From Monto et al. [30].
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being reduced by almost half compared with
placebo, and reduced in severity [31,32].
In an important study in the community of
oseltamivir [33], 629 healthy, non-immunized
adults aged 18–65 years presenting within 36 h
of onset and with a temperature of 38 8C or more
plus at least one respiratory symptom and one
constitutional symptom were enrolled (Table 4).
Individuals were randomized to one of three
treatment groups: oseltamivir, 75 mg or oseltami-
vir, 150 mg twice daily for 5 days, or placebo. In
total, 374 participants were confirmed to have
influenza (60%). The duration of illness from the
initiation of therapy was reduced by approxi-
mately 30% in the oseltamivir groups. In the 75-
mg group, the median duration of illness was
reduced to 3 days, compared to 4.3 days in the
placebo group (P< 0.001), and in the 150-mg
group, the duration was reduced to 2.9 days
(P< 0.001). There was also a significant decrease
in the symptom score AUC as a measure of the
severity of illness. Oseltamivir-treated volunteers
reported more rapid return to normal health and
usual activities. Additionally, the incidence of
secondary complications in subjects with influ-
enza, predefined as pneumonia, bronchitis, sinu-
sitis, and otitis media, was reduced from 15% in
placebo recipients to 5–9% in the two oseltamivir-
treated groups. Antibiotic prescriptions for these
complications were reduced (Table 5).
In summary, both NA inhibitor drugs, Relenza
and Tamiflu, show significant therapeutic antiviral
activity in the community. The challenge now will
be the reorganization of clinics and doctors’ surge-
ries to allow rapid access of ill patients to the new
drugs. All the recent trials have shown that reli-
ance on a triad of symptoms (temperature, cough,
and headache) can allow a doctor to diagnose
influenza accurately, especially if virologic surveil-
lance has identified influenza in the community.
Table 4 Effects of oseltamivir on duration and severity of illness [33]
Influenza-infected participants All treated participants
Placebo
(n¼ 129)
Oseltamivir,
75 mg
(n¼ 124)
Oseltamivir,
150 mg
(n¼ 121)
Placebo
(n¼ 209)
Oseltamivir,
75 mg
(n¼ 210)
Oseltamivir,
150 mg
(n¼ 208)
Illness duration, median
(95% Cl), h
103.3 71.5 69.9 97.0 76.3 74.3
P-value < 0.001 0.006 <0.004 0.004
Illness severity,
median score
963 597 626 887 686 629
P-value <0.001 <0.001 <0.001 <0.001
Return to normal health,
median (95% Cl), h
178 132 154 178 134 155
P-value <0.001 0.03 <0.001 0.03
Return to normal activity,
median (95% Cl), h
225 157 180 230 173 202
P-value 0.02 0.05 0.01 0.10
Table 5 Effect of oseltamivir on the
number of influenza-infected pa-
tients experiencing secondary com-
plications [33]
Study group
Complication
Placebo
(n¼ 129)
Oseltamivir, 75 mg
(n¼ 124)
Oseltamivir,
150 mg (n¼ 121)
Otitis media 1 0 0
Sinusitis 11 6 4
Bronchitis 8 5 2
Pneumonia 1 0 0
Any secondary
complication (%)
19 (15) 11 (9)a 6 (5)a
Antibiotic use (%) 14 (11) 8 (6)b 4 (3)b
aCombined oseltamivir results versus placebo (Fisher exact test), P¼ 0.03.
bCombined oseltamivir results versus placebo (Fisher exact test), P¼ 0.05.
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D R U G R E S I S T A N C E A N D
N E U R A M I N I D A S E I N H I B I T O R S :
D R U G - R E S I S T A N T M U T A N T S H A V E
R E D U C E D V I R U L E N C E
The most common mutation in the NA gene
selected by exposure to NA inhibitors in vitro is
an amino acid substitution of a lysine (K) for a
conserved arginine (R) at position 292, in influenza
N2 NA. The R292K mutation has been selected by
oseltamivir carboxylate, zanamivir, and RWJ-
270201, a third NA inhibitor. An H274Y mutation
in N1 has also been selected in vitro by oseltamivir
carboxylate, and in vivo in an HINI influenza virus
challenge study with oseltamivir phosphate in
healthy volunteers. The most common N2 muta-
tion arising in vitro under the selective pressure of
zanamivir has been that of the conserved Glu119
residue in the NA active site, causing a 100-fold
reduction in the sensitivity of the enzyme to zana-
mivir. Importantly, virus carrying the zanamivir-
selected mutation is attenuated in infectivity in
mice and in pathogenicity in ferrets. There are no
mutations selected by oseltamivir carboxylate at
position 119 in vitro, but E119V has arisen clinic-
ally during oseltamivir phosphate treatment in
just two patients infected with influenza A virus
of the H3N2 subtype. No NA mutations giving rise
to resistance have yet been generated by oseltami-
vir in influenza B NA in vitro, although there is
some evidence that zanamivir in vivo has induced
the development of a resistant mutation in influ-
enza B NA in an immunocompromised child.
The incidence of resistant virus has been shown
to be low, and resistant virus, where it does occur,
is detected only transiently, arising late in infection
and being cleared normally. In one clinical study
in which 385 patients were treated for naturally
acquired influenza infection [33], only one patient
was found to shed virus that carried NA with
reduced sensitivity to oseltamivir. This patient
received 75 mg of oseltamivir phosphate twice
daily. The virus isolated from a post-treatment
nasal swab carried NA with the R292K mutation.
The overall fitness (infectivity, replicative abil-
ity, and pathogenicity) of the virus carrying the
R292K mutation in the NA gene was reduced in
both mouse and ferret models of influenza. The
compromised nature of the virus with R292K NA
is consistent with the clinical course of influenza
illness in the patients found to carry R292K influ-
enza virus. These patients’ symptom scores were
generally indistinguishable from those of patients
with wild-type virus, and the patients continued to
recover normally, following emergence of resis-
tant virus at time points late in infection. Thus
there was no evidence for enhanced pathogenicity
of the resistant viruses in humans, and no con-
sequences for the patient of viral R292K NA muta-
tions occurring during the course of infection.
The other NA mutations that have arisen with
oseltamivir treatment of naturally acquired influ-
enza infection, again with low frequency, are
H274Y (one patient) and E119V (two patients).
As for patients carrying R292K virus, there were
no changes in symptom score and recovery for the
patients when H274Y and E119V were present in
the viral NA.
M A N A G E M E N T O F E P I D E M I C
I N F L U E N Z A I N T H E V A R I O U S
S U S C E P T I B L E P O P U L A T I O N
G R O U P S
The recent clinical studies with the NA inhibitors
described above have confirmed the earlier find-
ings for amantadine and rimantadine that rapid
intervention with antivirals can either ameliorate
symptoms in an already infected person or pre-
vent the spread of influenza in family groups. But
how are the new drugs actually to be used, and,
more importantly, how can the totality of live and
inactivated vaccines, amantadine and the NA inhi-
bitors be best applied to combat both pandemic
and epidemic influenza? There are large differ-
ences in the costs of these preventatives and thera-
pies, as well as in clinical experience, and in
effectiveness against viral subtypes (Table 6).
It would now appear that different clinical man-
agement approaches will apply to various sub-
groups of patients (Table 7). We will briefly
review the different community sectors.
The at-risk group in epidemic years
There is a scientific and medical consensus that
inactivated influenza vaccines should continue to
be the cornerstone of influenza management in the
elderly and at-risk groups. Indeed, for the winter
2000/2001 in the UK, 10 million doses of vaccine
were administered to the 7% of the population
who are at risk of serious complications during an
influenza infection. Other European countries and
the USA have immunized higher numbers of
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vulnerable patients. This at-risk group is made up
of everyone over the age of 65 years, and persons
of any age who are diabetic or who have chronic
heart, kidney or respiratory disease. However, it is
acknowledged that influenza vaccine is not 100%
protective against disease, and certainly not
against infection. Therefore, each year a propor-
tion of previously vaccinated at-risk persons will
become infected with influenza and be vulnerable
to severe respiratory complications. Also, perhaps
30–40% of the at-risk group will not receive vac-
cine. These persons are excellent candidates for
chemotherapy with either amantadine, the new
NA inhibitors, or both.
Children—the virus spreaders in epidemic
and pandemic years
There is substantial evidence that children consti-
tute a key group in the spread of influenza and,
indeed, other respiratory viruses. There has been
renewed interest in the application of live
attenuated influenza vaccines to prevent virus
spread among children, and thereby to amelio-
rate spread from children to adults, including the
vulnerable elderly. A re-evaluation of vaccination
policy in Japan during the 1970s and 1980s, which
used inactivated influenza vaccine in children, has
shown that the strategy may have reduced hospi-
talization and death in the elderly.
Amantadine at reduced dosage can be used for
therapy or prophylaxis in children. However, at
present there are only limited clinical data for the
NA inhibitors in children.
The working population
Although there have been studies in the past of the
use of vaccine, and also rimantadine, in large
cohorts of factory workers, more often influenza
has not been managed clinically in this important
group. Generally, the advice has been not to bother
the doctor, to self-administer paracetamol, and to
stay in bed. But each influenza epidemic brings a
Table 6 Licensed antivirals and vaccines for use against influenza
Antiviral or vaccine
Clinical
experience
Cost of course
(approximate) Side effects Drug resistance
Amantadine 30 years £5 Rare if dosage
reduced
Detected but have no
growth advantage
Rimantadine 30 years £5 Rare Detected but have no
growth advantage
Zanamivir 5 years £25 Rare Detected but have a
growth and virulence
disadvantage
Oseltamivir 2 years £25 (estimate) Rare Detected but have a
growth and virulence
disadvantage
Subunit HA/NA vaccine 20 years £5 Rare NA
Live attenuated cold-adapted (ca) vaccines 20 years £10 Rare NA
Table 7 The clinical management of influenza in epidemic years with antivirals and vaccines
Vaccines Antiviral
Group Live attenuated Inactivated M2 blockers
Neuraminidase
inhibitors
At risk population No Yes Yes Yes
Children as a group of super-spreaders Yes No Yes No
Young and other active members of societyy No No Yes Yes
Hospital staff and patients No Yes Yes Yes
Elderly persons’ homes, staff and patients No Yes Yes Yes
Note that the differentiation of influenza A from influenza B is required for the use of amantadine/rimantadine.
Approximately 7% of the population.
y<65 years.
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toll in hospital admissions and deaths among this
unprotected group in the population. Approxi-
mately half of the deaths rated in Figure 1 were
of persons in younger age groups. In addition,
there is significant economic disruption in this
community group.
The NA inhibitors could form an ideal group of
drugs for large-scale therapeutic use in this group,
although, of course, cost is a factor. With evidence
of influenza A in the community, rather than influ-
enza B, amantadine or rimantadine could also be
extremely useful drugs, especially for prophylaxis.
Hospital patients and staff
Influenza outbreaks place secondary care services
under particular pressure for acute admission. In
studies in the USA, during some winters as many
as 140% of excess admissions were attributed to
influenza. No nurse or doctor suffering from
chicken pox, measles, hemorrhagic fever or hepa-
titis would be found helping patients in a modern
hospital. Unfortunately, at least up to the present
time, influenza has been viewed differently, and
there is no doubt that hospital staff sometimes
carry on working with this infection. Obviously,
influenza is not being managed correctly under
these circumstances, because the virus could be
introduced into the ward of a hospital.
A few studies have examined the effect of vac-
cination of hospital staff and detected some reduc-
tion in influenza in wards where a high percentage
of staff were vaccinated. However, hospitals do
suffer from high staff turnover, making vaccina-
tion policies difficult to maintain. Chemopro-
phylaxis or therapy with amantadine and/or the
new NA inhibitors could now play an important
role.
T H E T H R E A T O F P A N D E M I C
I N F L U E N Z A A N D T H E U S E
O F A N T I V I R A L S
Influenza is a unique virus in having two epide-
miologic forms, epidemics and pandemics, and
management of community illness will be differ-
ent in each case. It is quite clear that effective
utilization of antiviral drugs to combat a pandemic
virus will depend upon the prior widespread use
of the drugs during interpandemic years. By defi-
nition, most persons would be vulnerable to infec-
tion with a new pandemic virus, although during
epidemic years those over 65 years of age are most
vulnerable to complications. It is not reasonable to
deduce that antivirals can be stored during inter-
pandemic years and only used in a pandemic. The
best approach would be consistent and detailed
clinical use of antivirals and vaccines to prevent
the year-to-year medical and economic impact of
influenza. In this manner, physicians and nurses
would become familiar with influenza as a unique
disease entity, and, at the time of a pandemic,
considerable clinical expertise in the use of anti-
virals would have accumulated. The WHO has
requested each member state to produce a pan-
demic plan, but few governments have responded
to date. We have recently published a focus alert
document to highlight concern about this lack of
preparation [34]. European countries are now con-
sidering a strategy of stockpiling anti-influenza
drugs; this, alongside more clinical use each year,
could be a significant investment in future com-
munity care in Europe.
The essential objectives of a pandemic plan are
to alert scientific, medical and political groups, and
to reduce the morbidity and mortality from influ-
enza illness, and thereby to increase the ability of a
community to cope with large numbers of people
who are ill, at home and in hospital, and dying,
and to ensure that essential services are main-
tained [35].
The date of the next influenza pandemic is
unknown. Intervals between previous pandemics
have varied from 11 to 42 years, with no recogniz-
able pattern. Thus, previous pandemics have been
caused by influenza A viruses in 1889, 1918, 1957,
and 1968 [36]. Re-emergence of an H2 or N7 or H5
component has been anticipated by some as the
most likely event leading to a pandemic, and 15
hemagglutinins exist in nature, particularly in bird
reservoirs.
In two pandemics (1957 and 1968), new influ-
enza viruses emerged in the Far East, whereas in
two earlier pandemics (1889 and 1918), the virus
arose in Europe [36], in Russia and France respec-
tively. In all cases, the new pandemic virus spread
along trade and transportation routes. The two
most recent pandemic strains have spread world-
wide in about 6–12 months, although successive
waves of illness may occur over a longer period.
The 1918 pandemic was recognized in France in
the early months of 1916, and by April 1918 was
widespread in western Europe. During the spring
and summer, large numbers of people were
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affected with relatively mild disease. The high
mortality occurred in a later wave in the autumn
[36]. It does appear that the evolution of a pan-
demic is complex.
Pandemic influenza may appear at any time of
the year, not necessarily during the ‘normal’ influ-
enza season (November to March in the northern
hemisphere). In most pandemics, activity can be
expected to last 6–8 weeks, although in 1968–69
lower levels of activity continued for 3–4 months.
This relatively short period of the outbreak, as
in epidemic years, allows prophylactic strategies
with antivirals to be implemented.
E S T I M A T E S O F I N C I D E N C E O F
I L L N E S S I N A P A N D E M I C
In 1918, about 23% of the UK population devel-
oped influenza, in the 1957 Asian influenza pan-
demic an estimated 17% of the population suffered
from influenza illness; and in 1969 the Hong Kong
virus produced illness in 8% of the adult popula-
tion. It could be safely predicted that each clinical
case would be accompanied by a non-clinical case
of influenza.
In normal years, although most influenza in-
fection occurs in children, the serious morbidity
and mortality occurs almost entirely among
elderly people with underlying chronic disease.
A different pattern may emerge in a pandemic, as
it did in 1918. The 1918–19 pandemic affected
mainly healthy young adults, and seemed to spare
those at the extremes of life. Similarly, in 1957, the
brunt was suffered by schoolchildren and young
adults. Therefore, it is clear that clinical manage-
ment of influenza with antivirals will differ in a
pandemic year compared to the interpandemic
period.
M O R T A L I T Y A N D M O R B I D I T Y I N
A P A N D E M I C Y E A R
Of course, the 1918 pandemic dominates the
records of infectious disease during the 20th cen-
tury, and indeed for the previous five centuries.
The worst-case scenarios of a new pandemic indi-
cate that, with the current massive world popula-
tion, rapidity of transport, and persons afflicted
with HIV, mortality in a new pandemic could
approach that of 1918 [37]. In 1957, when the
illness was, on the whole, milder compared to
the other pandemics of the 20th century, more
than 30 000 deaths occurred in England and Wales.
Estimates ranged from 1.3 to 3.5 deaths/1000
cases, and two-thirds of the deaths were of people
aged over 55 years.
In a pandemic, the number of new general
practice consultations for influenza-like illness
can be expected to exceed 500/100 000 population
per week during a pandemic; a medical practice of
10 000 patients would therefore expect to see at
least 50 new patients per week. Pandemics also
have a marked effect on hospital admissions. Dur-
ing September and October 1957, between 25 000
and 30 000 more cases of acute respiratory infec-
tion were admitted to hospitals in England and
Wales than would have been expected at that time
of year.
T H E I M P A C T O F P A N D E M I C S O N
T H E E C O N O M Y
Not unexpectedly, pandemics have a serious effect
on the economy. In 1957 in the UK, new sickness
benefit claims by those working and aged 15–
64 years increased by 2.5 million (of 17.5 million
insured). Among the uninsured, an additional 1.5
million absences were estimated. Of the insured
population, 8–10% were estimated to have lost 3
working days at home during the epidemic. In the
Hong Kong pandemic of 1968, just over 1 million
excess sickness claims were received in England
over 5 months.
T H E K E Y E L E M E N T S I N R E D U C I N G
T H E M O R B I D I T Y A N D M O R T A L I T Y
F R O M P A N D E M I C I N F L U E N Z A
The morbidity and mortality of influenza can be
reduced by prophylaxis and vaccination, and by
best practice in the management of cases, including
drug therapy. However, it must be acknowledged
that prevention of influenza by immunization
and/or the use of antiviral agents will be possible
only to a limited extent, unless health authorities
agree to store a quantity of each antiviral drug and
also to use these drugs more proactively during
the interpandemic years. In any case, vaccine is
likely to be in short supply. Vaccine production
takes time and is subject to various rate-limiting
factors, and demand will be high worldwide.
Vaccine will have to be distributed equitably
and administered to predetermined priority
groups. Also, it is not so certain that antiviral drugs
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will be available in any quantity unless the drugs
are used more during interpandemic years. In this
case, production and storage of drugs will have
reached quite high levels, and possibly only a
three-to-four-fold increase will be required to cope
with a pandemic. The UK pandemic plan acknowl-
edges that the need to keep health and other essen-
tial services running will mean that, if vaccine and
antiviral drug supplies are limited, certain groups
in the community may need to take precedence
over the risk groups normally recommended for
vaccination during interpandemic years.
C O N C L U S I O N S
There is no doubting the impact of the Great
Influenza Pandemic in 1918 and the subsequent
pandemics in 1957 and 1968, and there is much to
be learnt from a study of the genome of that virus:
what is the virulence gene constellation, and what
is the biology of a global pathogenic virus? These
important questions led in the 20th century to four
exhumations of influenza victims in Alaska [38],
Spitsbergen [39] and, more recently, in the UK (J. S.
Oxford and R. Daniels, unpublished data) to
retrieve and study the genetic composition of this
virus and to correlate virulence with particular
genes. Nevertheless, these pandemic events are
rare and need to be considered carefully in the
complete context of antivirals and influenza. As
we have seen in the current review, antivirals will
have an important position in the combined
human arsenal against virus-induced pneumonia,
alongside vaccines and antibiotics for secondary
bacterial complications. However, this review has
also argued that success during a pandemic
equates not to the sudden discovery in govern-
ment warehouses of a stock of antivirals, but rather
to the step-by-step use of these same drugs in the
year-to-year conflict with this virus in epidemics.
Recently, concern about influenza, along with
tuberculosis and other public-health factors, has
been sidelined in many countries, but it is quite
clear that public-health issues are becoming
increasingly important in a fast-moving and
increasingly international society, where truly
‘no man is an island’. Medical science is often
visionary, but in the case of influenza this has
unfortunately not been the case.
Those implementing medical care systems,
often rather complacent about influenza and tend-
ing to muddle along with a label of ‘flu and the
common cold’, will need to change to accommo-
date these new therapeutic agents against influ-
enza. At present, the health systems in Europe
militate against the successful deployment of a
therapy in a disease where irreversible cellular
damage happens within hours of the symptoms
appearing. The recent proposals from NICE in the
UK have suggested that practice nurses be
empowered to issue prescriptions for zanamivir,
and this could be a major step towards the speedy
application of drugs. Ultimately, the drugs will
need to be registered as ‘over the counter’ before
the window of use of 36–48 h post-symptom onset
can be exploited fully by sufferers. There has been
a concern about drug resistance, but this will
occur with every drug against RNA viruses.
Fortunately, viruses resistant to the NA inhibitors
are less virulent than wild-type viruses, while
the virulence of those resistant to amantadine is
either equivalent to or less than that of wild-type
viruses.
Both the new NA blockers and the more com-
prehensively researched M2 channel blockers are
powerful inhibitors of influenza virus replication,
and can prevent death and serious disease in
animal models. There is every reason to suppose
that these compounds, used intelligently with or
without vaccines, will have a major impact on the
threatening disease of influenza as we know it
today.
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